Proteomic identification of differentially-expressed proteins in squamous cervical cancer

Gynecologic Oncology

Volumn 112, Issue 1, 2009, Pages 248-256

  Zhu, Xueqiong ^a   Lv, Jieqiang ^a   Yu, Lirong ^a   Zhu, Xuejie ^a   Wu, Jieli ^a   Zou, Shuangwei ^a   Jiang, Shanshan ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Cervical cancer; Mass spectrometry; Squamous cell carcinoma; Two dimensional gel electrophoresis

Indexed keywords

CALGRANULIN B; CELL PROTEIN; CYTOKERATIN 1; ENDOPLASMIC RETICULUM 60 PROTEASE; LAMIN A; LAMIN C; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; PROTEIN; PROTEIN KINASE TYK2; RIBOSOMAL PROTEIN S15; RIBOSOME PROTEIN; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; UNCLASSIFIED DRUG; VIMENTIN; ZINC FINGER PROTEIN; ZINC FINGER PROTEIN 217;

ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; TIME OF FLIGHT MASS SPECTROMETRY; TWO DIMENSIONAL GEL ELECTROPHORESIS; UTERINE CERVIX CANCER; WESTERN BLOTTING;

ADULT; BLOTTING, WESTERN; CALGRANULIN B; CARCINOMA, SQUAMOUS CELL; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM PROTEINS; PROTEOMICS; REPRODUCIBILITY OF RESULTS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TRANS-ACTIVATORS; TYK2 KINASE; UTERINE CERVICAL NEOPLASMS;

EID: 57649099252     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.09.045     Document Type: Article

References (39)

1. Petignat P., and Roy M. Diagnosis and management of cervical cancer. BMJ 335 (2007) 765-768
2. Tjalma W.A., Van Waes T.R., Van den Eeden L.E., and Bogers J.J. Role of human papillomavirus in the carcinogenesis of squamous cell carcinoma and adenocarcinoma of the cervix. Best Pract. Res. Clin. Obstet. Gynaecol. 19 (2005) 469-483
3. Matos A., Moutinho J., Pinto D., and Medeiros R. The influence of smoking and other cofactors on the time to onset to cervical cancer in a southern European population. Eur. J. Cancer Prev. 14 (2005) 485-491
4. Delvenne P., Herman L., Kholod N., Caberg J.H., Herfs M., Boniver J., et al. Role of hormone cofactors in the human papillomavirus-induced carcinogenesis of the uterine cervix. Mol. Cell. Endocrinol. 264 (2007) 1-5
5. Nijhuis E.R., Reesink-Peters N., Wisman G.B., Nijman H.W., van Zanden J., Volders H., et al. An overview of innovative techniques to improve cervical cancer screening. Cell. Oncol. 28 (2006) 233-246
6. Cibas E.S., Alonzo T.A., Austin R.M., Bolick D.R., Glant M.D., Henry M.R., et al. The MonoPrep Pap test for the detection of cervical cancer and its precursors. Part I: results of a multicenter clinical trial. Am. J. Clin. Pathol. 129 (2008) 193-201
7. Davey E., Barratt A., Irwig L., Chan S.F., Macaskill P., Mannes P., et al. Effect of study design and quality on unsatisfactory rates, cytology classifications, and accuracy in liquid-based versus conventional cervical cytology: a systematic review. Lancet 367 (2006) 122-132
8. Arbyn M., Bergeron C., Klinkhamer P., Martin-Hirsch P., Siebers A.G., and Bulten J. Liquid compared with conventional cervical cytology: a systematic review and meta-analysis. Obstet. Gynecol. 111 (2008) 167-177
9. Martin C.M., Kehoe L., Spillane C.O., and O'Leary J.J. Gene discovery in cervical cancer: towards diagnostic and therapeutic biomarkers. Mol. Diagn. Ther. 11 (2007) 277-290
10. Ng G., Winder D., Muralidhar B., Gooding E., Roberts I., Pett M., et al. Gain and overexpression of the oncostatin M receptor occur frequently in cervical squamous cell carcinoma and are associated with adverse clinical outcome. J. Pathol. 212 (2007) 325-334
11. Sun de J., Liu Y., Lu D.C., Kim W., Lee J.H., Maynard J., et al. Endothelin-3 growth factor levels decreased in cervical cancer compared with normal cervical epithelial cells. Hum. Pathol. 38 (2007) 1047-1056
12. Nishigaki R., Osaki M., Hiratsuka M., Toda T., Murakami K., Jeang K.T., et al. Proteomic identification of differentially-expressed genes in human gastric carcinomas. Proteomics 5 (2005) 3205-3213
13. Murphy L., Clynes M., and Keenan J. Proteomic analysis to dissect mitoxantrone resistance associated proteins in a squamous lung carcinoma. Anticancer Res. 27 (2007) 1277-1284
14. Veenstra T.D., Prieto D.A., and Conrads T.P. Proteomic patterns for early cancer detection. Drug Discov. Today 9 (2004) 889-897
15. Lin Y.W., Lai H.C., Lin C.Y., Chiou J.Y., Shui H.A., Chang C.C., et al. Plasma proteomic profiling for detecting and differentiating in situ and invasive carcinomas of the uterine cervix. Int. J. Gynecol. Cancer 16 (2006) 1216-1224
16. Choi Y.P., Kang S., Hong S., Xie X., and Cho N.H. Proteomic analysis of progressive factors in uterine cervical cancer. Proteomics 5 (2005) 1481-1493
17. Bae S.M., Lee C.H., Cho Y.L., Nam K.H., Kim Y.W., Kim C.K., et al. Two-dimensional gel analysis of protein expression profile in squamous cervical cancer patients. Gynecol. Oncol. 99 (2005) 26-35
18. Wong Y.F., Cheung T.H., Lo K.W., Wang V.W., Chan C.S., Ng T.B., et al. Protein profiling of cervical cancer by protein-biochips: proteomic scoring to discriminate cervical cancer from normal cervix. Cancer Lett. 211 (2004) 227-234
19. Chao A., Wang T.H., Lee Y.S., Hsueh S., Chao A.S., Chang T.C., et al. Molecular characterization of adenocarcinoma and squamous carcinoma of the uterine cervix using microarray analysis of gene expression. Int. J. Cancer 119 (2006) 91-98
20. Yim E.K., Lee K.H., Kim C.J., and Park J.S. Analysis of differential protein expression by cisplatin treatment in cervical carcinoma cells. Int. J. Gynecol. Cancer 16 (2006) 690-697
21. Yim E.K., Lee M.J., Lee K.H., Um S.J., and Park J.S. Antiproliferative and antiviral mechanisms of ursolic acid and dexamethasone in cervical carcinoma cell lines. Int. J. Gynecol. Cancer 16 (2006) 2023-2031
22. Lee K.H., Yim E.K., Kim C.J., Namkoong S.E., Um S.J., and Park J.S. Proteomic analysis of anti-cancer effects by paclitaxel treatment in cervical cancer cells. Gynecol. Oncol. 98 (2005) 45-53
23. Yim E.K., Lee K.H., Bae J.S., Namkoong S.E., Um S.J., and Park J.S. Proteomic analysis of antiproliferative effects by treatment of 5-fluorouracil in cervical cancer cells. DNA Cell. Biol. 23 (2004) 769-776
24. Castagna A., Antonioli P., Astner H., Hamdan M., Righetti S.C., Perego P., et al. A proteomic approach to cisplatin resistance in the cervix squamous cell carcinoma cell line A431. Proteomics 4 (2004) 3246-3267
25. Yao R., Lopez-Beltran A., Maclennan G.T., Montironi R., Eble J.N., and Cheng L. Expression of S100 protein family members in the pathogenesis of bladder tumors. Anticancer Res. 27 (2007) 3051-3058
26. Sewell D.A., Yuan C.X., and Robertson E. Proteomic signatures in laryngeal squamous cell carcinoma. ORL J. Otorhinolaryngol. Relat. Spec. 69 (2007) 77-84
27. Verma A., Kambhampati S., Parmar S., and Platanias L.C. Jak family of kinases in cancer. Cancer Metastasis Rev. 22 (2003) 423-434
28. Ide H., Nakagawa T., Terado Y., Kamiyama Y., Muto S., and Horie S. Tyk2 expression and its signaling enhances the invasiveness of prostate cancer cells. Biochem. Biophys. Res. Commun. 369 (2008) 292-296
29. Thompson J.E. JAK protein kinase inhibitors. Drug News Perspect. 18 (2005) 305-310
30. He Q.Y., Chen J., Kung H.F., Yuen A.P., and Chiu J.F. Identification of tumor-associated proteins in oral tongue squamous cell carcinoma by proteomics. Proteomics 4 (2004) 271-278
31. Hermani A., Hess J., De Servi B., Medunjanin S., Grobholz R., Trojan L., et al. Calcium-binding proteins S100A8 and S100A9 as novel diagnostic markers in human prostate cancer. Clin. Cancer Res. 11 (2005) 5146-5152
32. Cross S.S., Hamdy F.C., Deloulme J.C., and Rehman I. Expression of S100 proteins in normal human tissues and common cancers using tissue microarrays: S100A6, S100A8, S100A9 and S100A11 are all overexpressed in common cancers. Histopathology 46 (2005) 256-269
33. Gebhardt C., Németh J., Angel P., and Hess J. S100A8 and S100A9 in inflammation and cancer. Biochem. Pharmacol. 72 (2006) 1622-1631
34. Arai K., Teratani T., Kuruto-Niwa R., Yamada T., and Nozawa R. S100A9 expression in invasive ductal carcinoma of the breast: S100A9 expression in adenocarcinoma is closely associated with poor tumour differentiation. Eur. J. Cancer 40 (2004) 1179-1187
35. Ito Y., Arai K., Ryushi, Nozawa, Yoshida H., Tomoda C., et al. S100A9 expression is significantly linked to dedifferentiation of thyroid carcinoma. Pathol. Res. Pract. 201 (2005) 551-556
36. Quinlan K.G., Verger A., Yaswen P., and Crossley M. Amplification of zinc finger gene 217 (ZNF217) and cancer: when good fingers go bad. Biochim. Biophys. Acta 1775 (2007) 333-340
37. Sun G., Zhou J., Yin A., Ding Y., and Zhong M. Silencing of ZNF217 gene influences the biological behavior of a human ovarian cancer cell line. Int. J. Oncol. 32 (2008) 1065-1071
38. Huang G., Krig S., Kowbel D., Xu H., Hyun B., Volik S., et al. ZNF217 suppresses cell death associated with chemotherapy and telomere dysfunction. Hum. Mol. Genet. 14 (2005) 3219-3225
39. Mino T., Mori T., Aoyama Y., and Sera T. Cell-permeable artificial zinc-finger proteins as potent antiviral drugs for human papillomaviruses. Arch. Virol. 153 (2008) 1291-1298